Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2204-2211

  Macías, Juan ^a   del valle, José ^a   Rivero, Antonio ^b   Mira, José A ^a   Camacho, Ángela ^b   Merchante, Nicolás ^a   Pérez Camacho, Inés ^c   Neukam, Karin ^a   Rivero Juárez, Antonio ^b   Mata, Rosario ^a   Torre Cisneros, Julián ^b   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL DE PONIENTE   (Spain)

Author keywords

HCV; Liver fibrosis; Sustained virological response; Transient liver elastometry

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VIREMIA;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; ELASTICITY; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 77957229964     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq272     Document Type: Article

References (23)

1. Wise M, Bialek S, Finelli L et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008; 47: 1128-35.
2. Pineda JA, Romero-Gómez M, Díaz-García F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-89.
3. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
4. Veldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
5. Bruno S, Zuin M, Crosignani A et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 2009; 104: 1147-58.
6. Berenguer J, Alvarez-Pellicer J, Martín PM et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
7. Cammà C, Di Bona D, Schepis F et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.
8. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
9. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
10. Lissen E, Clumeck N, Sola R et al. Histological response to peg-IFN alpha-2a (40 kD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20: 2175-81.
11. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
12. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
13. Fraquelli M, Rigamonti C, Casazza G et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73.
14. Neukam K, Recio E, Camacho A et al. Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Eur J Gastroenterol Hepatol 2010; 22: 801-7.
15. Lucidarme D, Foucher J, Le Bail B et al. Factors of accuracy of transient elastography (FibroScan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-9.
16. Vergniol J, Castera L, Duburque C et al. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009; 16: 132-40.
17. Ogawa E, Furusyo N, Toyoda K et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-34.
18. Mira JA, Valera-Bestard B, Arizcorreta-Yarza A et al. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Antivir Ther 2007; 12: 523-9.
19. Macías J, Recio E, Vispo E et al. Application of transient elastography to differentiate mild from moderate to severe liver fibrosis in HIV/HCV-coinfected patients. J Hepatol 2008; 49: 916-22.
20. Vergara S, Macías J, Rivero A et al. The use of transient elastography for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969-74.
21. Vispo E, Barreiro P, Del Valle J et al. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther 2009; 14: 187-93.
22. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
23. Bruno S, Battezzati PM, Bellati G et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001; 34: 748-55.